Lipton A, Harvey H A, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, White D S
Cancer. 1983 Jan 1;51(1):57-60. doi: 10.1002/1097-0142(19830101)51:1<57::aid-cncr2820510114>3.0.co;2-v.
One-hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette-Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs-Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients treated with C. parvum.
116例I期和II期恶性黑色素瘤患者被随机分为两组，分别接受卡介苗（BCG）（Tice株）治疗或皮下注射短小棒状杆菌（Burroughs-Wellcome公司生产）治疗。生存分析显示，68例I期患者接受这两种治疗方式的疗效无差异。接受短小棒状杆菌治疗的II期患者复发率显著降低。
